Edition:
India

Kamada Ltd (KMDA.OQ)

KMDA.OQ on NASDAQ Stock Exchange Global Select Market

4.70USD
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
$4.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
28,342
52-wk High
$8.55
52-wk Low
$3.75

Chart for

About

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 31.15 16.44
EPS (TTM): -- -- --
ROI: -- 14.99 10.62
ROE: -- 16.33 14.20

BRIEF-Kamada announces new supply agreement with international organization for KamRAB

* Kamada announces new supply agreement with international organization for KamRAB for post-exposure prophylaxis against rabies infection

21 Nov 2017

BRIEF-Kamada and ‍Chiesi Farmaceutici terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy

* Kamada Ltd - Co, ‍chiesi Farmaceutici S.P.A. mutually agree to terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy

20 Nov 2017

BRIEF-Kamada announces CFO transition

* Kamada Ltd - Gil Efron, (deputy CEO) & Chief Financial Officer (CFO), recently informed company of his plan to leave at end of year

18 Sep 2017

BRIEF-Brosh Capital's Amir Efrati reports 6.2 pct stake in Kamada Ltd

* Brosh Capital Partners LP's Amir Efrati reports 6.2 Pct stake in Kamada Ltd as of Sept 1 - SEC filing Source text: (http://bit.ly/2h49AAz) Further company coverage:

14 Sep 2017

BRIEF-Kamada announces pricing of public offering of ordinary shares

* Kamada Ltd - pricing of 3.33 million of its ordinary shares at a price of $4.50 per share Source text for Eikon: Further company coverage:

28 Jul 2017

BRIEF-Kamada to withdraw European Marketing Authorization application for inhaled ALPHA-1 antitrypsin

* Kamada announces withdrawal of European Marketing Authorization application for inhaled ALPHA-1 antitrypsin for treatment of ALPHA-1 antitrypsin deficiency disease

22 Jun 2017

BRIEF-Kamada receives additional milestone payment from Shire PLC

* Kamada receives additional milestone payment under Glassia exclusive supply and distribution agreement with Shire

12 Jun 2017

BRIEF-Kamada provides update on clinical program for alpha-1 antitrypsin IV treatment

* Provides update on clinical program for alpha-1 antitrypsin IV for treatment of graft-versus-host disease

07 Jun 2017

Earnings vs. Estimates